Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.

By J. Christensen, T. Grønborg, M. J. Sørensen, D. Schendel, E. Parner, L. Pedersen, M. Vestergaard. Journal of the American Medical Association (JAMA), 2013

1,207 citations recorded by the source corpus.

Subfields: Cognitive Neuroscience, Pediatrics, Perinatology and Child Health, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/1113ae39c72b0a72b91c7210cf8e764da92d0106

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. K. Lyall
2. J. Daniels
3. L. Croen
4. M. Fallin
5. Christine Ladd-Acosta
6. Brian K Lee
7. B. Park
8. Nathaniel W. Snyder

Citations in the corpus

• Mechanisms underlying microbial-mediated changes in social behavior in mouse models of Autism Spectrum Disorder (2018, neutral): “More specifically, clinical studies have shown that maternal exposure to VPA, a branched short-chain fatty acid used as an antiepileptic drug, is associated with increased risk of ASD incidence in offspring (Christensen et al., 2013; Ornoy, 2009).”
• The Changing Epidemiology of Autism Spectrum Disorders (2016, background): “Recent studies of antiepileptics (21, 35, 179) and B2ARs (39, 67) have consistently identified increased risk of ASD or autistic traits with exposure during pregnancy (35, 179).”